key: cord-1028508-gi6hekpu
authors: Llau, J. V.; Ferrandis, R.; Sierra, P.; Hidalgo, F.; Cassinello, C.; Gómez-Luque, A.; Quintana, M.; Amezaga, R.; Gero, M.; Serrano, A.; Marcos, P.
title: SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection
date: 2020-08-04
journal: nan
DOI: 10.1016/j.redare.2020.05.007
sha: bf8dc20553d26db91b3df50c16d062b970ccb59b
doc_id: 1028508
cord_uid: gi6hekpu

Abstract The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID-19, mainly causes alterations in the respiratory system. In severely ill patients, the disease often evolves into an acute respiratory distress syndrome that can predispose patients to a state of hypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatory process linked to this pathology, including the additional thrombotic factors present in many of the patients. In view of the need to optimise the management of hypercoagulability, the working groups of the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and of Intensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observed in severely ill patients with COVID-19. These recommendations include prophylaxis of venous thromboembolic disease in these patients, and in the peripartum, management of patients on long-term antiplatelet or anticoagulant treatment, bleeding complications in the course of the disease, and the interpretation of general alterations in haemostasis.

respiratorio. En los pacientes graves, con frecuencia la enfermedad evoluciona a un síndrome de distrés respiratorio agudo que puede predisponer a los pacientes a un estado de hipercoagulabilidad, con trombosis tanto a nivel venoso como arterial. Esta predisposición presenta una fisiopatología multifactorial, relacionada tanto con la hipoxia como con el grave proceso inflamatorio ligado a esta patología, además de los factores trombóticos adicionales presentes en muchos de los pacientes.

Ante la necesidad de optimizar el manejo de la hipercoagulabilidad, los grupos de trabajo de las Sociedades Científicas de Anestesiología-Reanimación y Terapéutica del Dolor (SEDAR) y de Medicina Intensiva, Crítica y de Unidades Coronarias (SEMICYUC), han desarrollado un consenso para establecer unas pautas de actuación frente a las alteraciones de la hemostasia observadas en los pacientes graves con infección por COVID-19. Estas recomendaciones incluyen la profilaxis de la enfermedad tromboembólica venosa en pacientes graves y en el periparto, el manejo de los pacientes en tratamiento crónico con fármacos antiagregantes o anticoagulantes, de las complicaciones hemorrágicas en la evolución de la enfermedad y de la interpretación de las alteraciones generales de la hemostasia.

The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID-19, mainly causes alterations in the respiratory system. In severely ill patients, the disease often evolves into an acute respiratory distress syndrome that can predispose patients to a state of hypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatory process linked to this pathology, including the additional thrombotic factors present in many of the patients.

In view of the need to optimise the management of hypercoagulability, the working groups of the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and of Intensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observed in severely ill patients with COVID-19 infection. These recommendations include prophylaxis of venous thromboembolic disease in these patients, and in the peripartum, management of patients on long-term antiplatelet or anticoagulant treatment, bleeding complications in the course of the disease, and the interpretation of general alterations in haemostasis. CoV-2 coronavirus infection, when it progresses to COVID-19, is frequently  associated with characteristic alterations of certain haematological parameters, as shown  in Table 1 [1] [2] [3] [4] [5] [6] [7] .

Several hypotheses have been put forward to explain this pattern of haematological behaviour 8 , including a hypercoagulable state, a reactivity typical of severe inflammation with endothelitis as a direct consequence of the action of the virus, and the respiratory distress-induced hypoxia frequently found in these cases 9, 10 . In any event, patients with severe COVID-19 appear to be at high risk of developing cardiovascular complications. Thrombotic events are particularly frequent -some studies have reported an overall incidence of venous thromboembolism of around 25% 11 and an incidence of thrombotic complications in critically ill patients of 31% 12 . Furthermore, an increase in microvascular thrombosis in the pulmonary circulation could play an important role in the course of respiratory failure 11, 13 .

The presence of previous cardiovascular disease, on the other hand, is a risk factor for severe disease and mortality. In addition, when treating these patients clinicians must take into account that the drugs used to treat COVID-19 might interact with their background treatment, which may need to be adjusted accordingly.

In these circumstances, it is important to establish prophylactic or therapeutic anticoagulant therapy that may benefit these patients. The aim of this study is to put forward recommendations for the management of these patients. Taking into account the lack of available evidence, these recommendation should be reviewed and modified on the basis of clinical experience and the emergence of new evidence.

An analysis of the characteristic pattern of increased D-dimer and fibrinogen appears to suggest an increase in procoagulant activity leading to an increase in fibrinolytic activity. In terms of pathophysiology, disseminated intravascular coagulation (DIC) can coexist with what has been called "sepsis-induced coagulopathy" (SIC) [14] [15] [16] (Table 2 ). The literature is all but silent in this respect, and the presence of DIC has been described in only 8.7% of cases (16 of 183 patients) after applying the D-dimer cut-off points previously proposed for critically ill patients 17 ; however, it was found in 71% of patients who died 2 . The D-dimer increase has been associated not only with greater clinical severity (deterioration of respiratory failure), but also with an increase in microclots in the pulmonary vascularisature 18 .

Patients with severe disease related to SARS-CoV-2 infection, particularly those admitted to intensive care units (ICU), are usually bedridden, connected to mechanical ventilation, under sedation, and frequently receiving neuromuscular blockers. Furthermore, the hypoxia and inflammatory activity characteristic of this disease can lead to a hypercoagulable state involving multiple mediators, which has been documented in cases of sepsis 19 . Therefore, it can be said that these patients are at particularly high risk of developing venous thromboembolism (VTE), and this complication must be evaluated in all cases 11,20 . The results of some studies currently suggest a trend towards an increase in VTE among patients with COVID-19 12, [21] [22] [23] [24] . Some studies published so far suggest that these cases can benefit from the J o u r n a l P r e -p r o o f administration of low molecular weight heparins (LMWH) 2 12 , albeit probably only in selected patients. Benefit from LMWH increases in parallel with an increase in Ddimer levels, regardless of whether or not the patients met DIC criteria 25 . In this study, the multivariate analysis concluded that the 3 independent risk factors for 28-day mortality were D-dimer increase, PT prolongation, and low platelet count. The authors also observed lower mortality in patients treated with LMWH or unfractionated heparin (UFH) at 28 days, in those with D-dimer levels more than 6 times the upper limit of normal, or with sepsis-induced coagulopathy (SIC scale ≥ 4).

There is no evidence to show the superiority of a particular LMWH dose, pending the results of studies currently underway. -In hospitalised patients with COVID-19 ( Fig. 1 J o u r n a l P r e -p r o o f -We recommend not suspending antithrombotic prophylaxis due to laboratory abnormalities in coagulation unless there is active bleeding or a decrease in the platelet count (<30 × 10 9 /l). -In patients at high risk of haemorrhage, mechanical thromboprophylaxis should be prioritised (intermittent pneumatic compression). In these circumstances, we suggest considering viscoelastic tests for additional haemostasis monitoring. -In patients at high risk of thrombosis, we suggest associating mechanical (intermittent pneumatic compression) and pharmacological prophylaxis.

Pregnant women have a 4-5 times higher risk of presenting VTE than non-pregnant women due to hormonal and mechanical changes (because the increased size of the pregnant uterus impairs venous return in the lower limbs and pelvis) and decreased mobility secondary to weight gain. Therefore, the risk of thrombosis during pregnancy and the puerperium is usually evaluated, and prophylactic treatment with LMWH is established accordingly.

There are very few data on SARS-CoV-2 infection during pregnancy. However, the possible effect of COVID-19 in pregnant women can be inferred from data on infection by other similar coronaviruses (severe acute respiratory syndrome [SARS-CoV] or middle east respiratory syndrome [MERS-CoV]).

Reports suggest that SARS-CoV-2 infection is associated with a hypercoagulable state, and although no studies have provided sufficient evidence to establish firm recommendations in infected pregnant patients, it has been suggested that these should be based on thrombotic risk factors and lab data that are known predictors of poor evolution. However, for obvious reasons, it is not possible to consider D-dimer in the context of the peripartum, so in this context only fibrinogen (given that fibrinogen levels are usually higher during pregnancy and postpartum, the cut point of thrombotic risk could be 7 g/l instead of 5 g/l), plasma ferritin and platelet count can be considered predictors of a hypercoagulable state

The recommendations for thromboprophylaxis in pregnant women with COVID-19 have been based on a review of recommendations on thrombophilia in pregnant women [26] [27] [28] , given that antithrombotic therapy is not mentioned in specific studies on the management of pregnant patients 29-31 .

At the end of pregnancy, both the route and time of delivery should be evaluated individually by a multidisciplinary team 28 . According to the multidisciplinary technical document "Management of pregnant patients and infants with COVID-19" 31 , if delivery can be performed by caesarean section, neuraxial anaesthesia (spinal, epidural or combined) should be the technique of choice, provided it is not contraindicated. 

Various pharmacological interactions between anticoagulant or antiplatelet drugs and drugs routinely administered to treat COVID-19 have been described. Table 3 shows the most significant interactions, although more detailed information can be found on the website of reference 32 .

The indications for chronic anticoagulation therapy are well known, and include atrial fibrillation, stroke, recent history of VTE, or mechanical heart valve 33 . Patients with COVID-19 infection who are being treated with an oral anticoagulant, either antivitamin K or direct oral anticoagulant, should continue with the therapy regardless J o u r n a l P r e -p r o o f of the course of the disease, provided it is not associated with bleeding, and a switch to the parenteral route should be considered 34 . Nevertheless, given the large number of interactions between orally administered anticoagulant drugs and drugs used to treat COVID-19 and the changes in their bioavailability in critically ill patients, the anticoagulation regimen should be based on the administration of parenteral drugs. Although both UFH and LMWH can be used, LMWH is preferred because the regimen is easy to manage and anticoagulation monitoring is only required in patients presenting kidney failure.

-We recommend maintaining Table 4 anticoagulants in patients requiring this therapy, according to their indications. -For anticoagulation maintenance, we do not recommend using drugs with antivitamin K action or direct oral anticoagulants, either due to their interactions or to the difficulty involved in managing or monitoring anticoagulant activity. -We recommend using LMWH at therapeutic doses (10,000 IU/24 h, 150 IU/kg/24 h or 100 IU/kg/12 h) for anticoagulation in these patients. It is impossible to recommend an optimal dosing protocol; instead, the protocol most widely used should be chosen in each case.

A n t i -p l a t e l e t t r e a t m e n t Antiplatelet therapy with acetylsalicylic acid (ASA) should be continued in patients previously receiving it or who develop a disease requiring this therapy. No important interactions between ASA and drugs commonly used in these patients have been described.

However, due to interactions with lopinavir/ritonavir 32 , clopidogrel (decreased conversion of the drug to its active metabolite, and therefore decreased pharmacological effect) and ticagrelor (increased plasma concentration) are not recommended. In patients requiring dual therapy (ASA plus a P2Y12 receptor inhibitor), prasugrel, which has fewer interactions, is recommended.

-ASA: we recommend continuing the ASA regimen started before onset of COVID-19 if indicated for secondary prevention. -Clopidogrel: not recommended due to the potential decrease in its effect when interacting with lopinavir/ritonavir. Consider replacing with prasugrel if necessary. -Ticagrelor: not recommended due to the potential increase in its effect when interacting with lopinavir/ritonavir. If it is administered as monotherapy and there is no contraindication, consider replacing it with ASA or prasugrel. -Prasugrel: recommended instead of clopidogrel or ticagrelor in patients requiring a P2Y12 receptor inhibitor antiplatelet agent.

-Dual therapy: in patients requiring dual therapy (ASA) + P2Y12 inhibitor), we suggest maintaining ASA in combination with LMWH at therapeutic doses as an alternative to AAS + prasugrel.

Interpretation of coagulation tests and bleeding management SARS-CoV-2 infection has not so far been associated with a significant incidence of bleeding complications, despite the reported alterations in standard clinical coagulation tests.

PT alterations can generally be classed as minor, since prolongation, if present, has little clinical significance. It is interesting to note that aPTT is within normal ranges in the vast majority of critically ill patients with COVID-19. This suggests that haemostasis is not affected and there is no bleeding tendency; therefore, empirical treatment should not be given on the basis of coagulation tests.

A moderate decrease in plasma antithrombin concentration to around 80% of activity has been observed 2 . Given that this decrease does not generally imply a clinically significant alteration, we do not recommend the systematic use of replacement therapy.

The fibrinolysis observed in this clinical setting, which is caused by an almost systematic increase in plasma D-dimer levels, as mentioned above, appears to derive from the lysis of microthrombi in the context of an inflammatory reaction involving multiple cellular and biochemical mediators. In the absence of experience with antifibrinolytics in COVID-19, it would be prudent to discourage the use of any such therapy in COVID-19 patient presenting bleeding.

There is no experience in the use of viscoelastic tests for the management of bleeding complications in seriously ill patients with COVID-19, therefore no recommendations can be established in this scenario. However, in cases of severe acute bleeding, parameters used in patients with severe acute bleeding in other clinical settings can be used to aid in decision-making.

On the basis of the foregoing and on recently published guidelines, we propose the following recommendations 20, 35 .

-We recommend not administering anticoagulants to correct the results of coagulation tests in the absence of significant bleeding. -If bleeding is present, we suggest administering plasma as the first option to treat bleeding (10-15 ml/kg), provided the PT-ratio is greater than 1.5. -We recommend not administering prothrombin complex concentrate as the first treatment option for bleeding in these patients due to the lack of experience and lack of safety data. -In patients with acute bleeding, we recommend maintaining plasma fibrinogen levels ≥ 1.5 g/l, preferably administering fibrinogen concentrate or cryoprecipitate instead of fresh plasma.

-In patients with acute bleeding, we recommend maintaining a platelet count of at least 50  10 9 /l, which is usually sufficient to achieve haemostasis, and we recommend performing platelet transfusion to achieve this level. -We do not recommend administering antithrombin in the context of SARS-CoV-2 infection. -We do not recommend administering tranexamic acid in this context, except in the case of severe bleeding and confirmation of hyperfibrinolysis by viscoelastic tests. -In patients presenting severe acute bleeding, we suggest basing the administration of haemostasis agents on the results obtained from viscoelastic tests, when available. -The use of factor VIIAa is not recommended in patients with COVID-19.

Severe SARS-CoV-2 infection most frequently affects patients with various comorbidities, particularly cardiovascular disease. This means that a considerable percentage of these patients will be receiving antiplatelet or anticoagulant drugs, and these therapies must be properly managed to ensure a good outcome. In addition, changes in haemostasis observed in patients with COVID-19 may imply an increased risk of developing thrombosis, so early administration of LMWH should be part of routine treatment.

Finally, any bleeding complications appearing in these patients should be treated with extreme caution, given their prothrombotic status and the multifactorial aetiology of such complications. 15 , Taylor et al. 16 and Dempfle et al. 17 . Table 3 Drug interactions between anticoagulants and antiplatelet agents and drugs commonly used in the treatment of patients with severe COVID-19 infection. ASA: acetylsalicylic acid; AVK: drugs with antivitamin K action; DAOA: direct acting oral anticoagulants; DAOC: direct acting oral anticoagulants; LMWH: low molecular weight heparin; UFH: unfractionated heparin. Source: Interactions with Experimental COVID-19 therapies 32 . 

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Covid-19 in critically ill patients in the Seattle Region -case series

Clinical Characteristics of Coronavirus Disease 2019 in China

The laboratory diagnosis of COVID-19 infection : Current Issues and Challenges

Hematologic parameters in patients with COVID-19 infection

Difference of coagulation features between severe pnaeumonia induced by SARS-CoV2 and non-SARS-CoV2

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Research

Clinical pathology of critical patient with novel Coronavirus Pneumonia (COVID-19)

Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation

New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: A retrospective analysis of a nationwide survey

Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation

Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score

Evaluation and Treatment Coronavirus (COVID-19)

Anticoagulant modulation of inflammation in severe sepsis

Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19

COVID-19 Complicated by Acute Pulmonary Embolism

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Thromboinflamation and the hypercoagulability of COVID

Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Antithrombotic Therapy, and Pregnancy. Antithrombotic Therapy and Prevention of Thrombosis

Management of inherited thrombophilia in pregnancy

Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis

Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection

Documento técnico Manejo de la mujer embarazada y el recién nacido con COVID-19 (Versión de 17 de marzo de 2020)

-Interactions with Experimental COVID-19 Therapies. Disponible en: www.covid19-druginteractions.org

Manejo perioperatorio y periprocedimiento del tratamiento antitrombótico: documento de consenso de SEC

Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Figure 1 Outline of thromboprophylaxis and management of anticoagulant and antiplatelet drugs in patients with COVID-19 infection

ASA: acetylsalicylic acid; AF: atrial fibrillation; AVK: antivitamin K; DD: D-dimer

DOA: direct oral anticoagulant; FIB: fibrinogen; GFR: glomerular filtration rate; HIT: heparin-induced thrombocytopaenia; IMV: invasive mechanical ventilation; LMWH: low molecular weight heparin; NR: normal range; NIMV: non-invasive mechanical ventilation